32 results on '"Kronbichler, Andreas"'
Search Results
2. Development of a Kidney Prognostic Score in a Japanese Cohort of Patients With Antineutrophil Cytoplasmic Autoantibody Vasculitis
- Author
-
Takeda, Rei, Takahashi, Kazuya, Kronbichler, Andreas, Akiyama, Daiichiro, Hanai, Shunichiro, Kobayashi, Yoshiaki, Matsuki, Ayako, Umibe, Takeshi, Ito, Chisaki, Sugimoto, Toyohiko, Sugiyama, Takao, Yoshida, Shun, Nishio, Yasuhide, Nukui, Ikuo, Nakashima, Ayumu, Wakabayashi, Hanae, Asanuma, Katsuhiko, Furuta, Shunsuke, Nakajima, Hiroshi, and Nakagomi, Daiki
- Published
- 2024
- Full Text
- View/download PDF
3. Exercise-Induced Fluid Retention, Cardiac Volume Overload, and Peripheral Edema in Ultra-Distance Cyclists
- Author
-
Gauckler, Philipp, Kesenheimer, Jana S., Leierer, Johannes, Kruus, Maren, Schreinlechner, Michael, Theurl, Fabian, Bauer, Axel, Denicolò, Sara, Egger, Alexander, Seeber, Beata, Mayer, Gert, Kolbinger, Fiona R., and Kronbichler, Andreas
- Published
- 2024
- Full Text
- View/download PDF
4. Clonal Hematopoiesis of Indeterminate Potential and Diabetic Kidney Disease: A Nested Case-Control Study
- Author
-
Denicolò, Sara, Vogi, Verena, Keller, Felix, Thöni, Stefanie, Eder, Susanne, Heerspink, Hiddo J.L., Rosivall, László, Wiecek, Andrzej, Mark, Patrick B., Perco, Paul, Leierer, Johannes, Kronbichler, Andreas, Steger, Marion, Schwendinger, Simon, Zschocke, Johannes, Mayer, Gert, and Jukic, Emina
- Published
- 2022
- Full Text
- View/download PDF
5. Kynurenine Pathway after Kidney Transplantation: Friend or Foe?
- Author
-
Zakrocka, Izabela, Urbańska, Ewa M., Załuska, Wojciech, and Kronbichler, Andreas
- Subjects
CHRONIC kidney failure ,RENAL replacement therapy ,INDOLEAMINE 2,3-dioxygenase ,KIDNEY transplantation ,GRAFT rejection ,TRYPTOPHAN - Abstract
Kidney transplantation significantly improves the survival of patients with end-stage kidney disease (ESKD) compared to other forms of kidney replacement therapy. However, kidney transplant recipients' outcomes are not fully satisfactory due to increased risk of cardiovascular diseases, infections, and malignancies. Immune-related complications remain the biggest challenge in the management of kidney graft recipients. Despite the broad spectrum of immunosuppressive agents available and more detailed methods used to monitor their effectiveness, chronic allograft nephropathy remains the most common cause of kidney graft rejection. The kynurenine (KYN) pathway is the main route of tryptophan (Trp) degradation, resulting in the production of a plethora of substances with ambiguous properties. Conversion of Trp to KYN by the enzyme indoleamine 2,3-dioxygenase (IDO) is the rate-limiting step determining the formation of the next agents from the KYN pathway. IDO activity, as well as the production of subsequent metabolites of the pathway, is highly dependent on the balance between pro- and anti-inflammatory conditions. Moreover, KYN pathway products themselves possess immunomodulating properties, e.g., modify the activity of IDO and control other immune-related processes. KYN metabolites were widely studied in neurological disorders but recently gained the attention of researchers in the context of immune-mediated diseases. Evidence that this route of Trp degradation may represent a peripheral tolerogenic pathway with significant implications for transplantation further fueled this interest. Our review aimed to present recent knowledge about the role of the KYN pathway in the pathogenesis, diagnosis, monitoring, and treatment of kidney transplant recipients' complications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function.
- Author
-
Zakrocka, Izabela, Nair, Gayatri, Soler, Maria Jose, Jhaveri, Kenar D., and Kronbichler, Andreas
- Subjects
KIDNEY glomerulus diseases ,KIDNEY transplantation ,TRANSPLANTATION of organs, tissues, etc. ,DISEASE risk factors ,IMMUNOSUPPRESSIVE agents ,PARANEOPLASTIC syndromes - Abstract
Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney transplant recipients, due to factors inherent to concomitant medication and common comorbidities. Recent advances in the field of molecular and clinical nephrology led to a significant improvement in our understanding of glomerular diseases and their more targeted treatment. On the other hand, introduction of novel anticancer drugs tremendously increased patients' survival, at the cost of kidney-related side effects. Our review aims to provide insights into diagnosis and treatment of paraneoplastic glomerular diseases, with a special attention to kidney transplant recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).
- Author
-
C Willcocks, Lisa, Qian, Wendi, Cader, Ruzaika, Gatley, Katrina, Siddiqui, Hira, Tabebisong, Endurance, Champion, Karlena, Kronbichler, Andreas, Lightstone, Liz, Jayne, David, Wilson, Edward, and Griffith, Megan
- Subjects
CLINICAL trials ,RANDOMIZED controlled trials ,NEPHROTIC syndrome ,B cells ,MONOCLONAL antibodies - Abstract
Background: Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) are a spectrum of disease causing the nephrotic syndrome (NS), characterised by proteinuria with debilitating oedema, as well as a high risk of venous thromboembolic disease and infection. Untreated, 50–60% patients with FSGS progress to end stage kidney disease after 5 years. These diseases respond to immunosuppression with high dose glucocorticoids, but 75% will relapse as the glucocorticoids are withdrawn, leading to significant morbidity associated with prolonged use. In children, the B cell depleting monoclonal antibody rituximab reduces relapse risk, but this drug has not been tested in randomised controlled trial in adults. Methods: 130–150 adults with new or relapsing MCD/FSGS, from UK Renal Units, are being randomised to receive either rituximab (two 1 g infusions two weeks apart) or placebo. Partipicipants are recruited when they present with nephrosis, and all are treated with glucocorticoids as per KDIGO guidelines. Once in remission, prednisolone is withdrawn according to a pre-specified regimen. If in remission at 6 months, participants receive a further dose of trial drug. If they relapse, they are unblinded, and if they have received placebo, they are offered open label rituximab with protocolised prednisolone as in the main phase of the trial. The primary end point is time from remission to relapse. A number of secondary endpoints will be assessed including the effect of rituximab on: (1) NHS and societal resource use and hence cost: (2) safety: (3) other measures of efficacy, such as achievement of partial and complete remission of NS and the preservation of renal function: (4) health status of participant. Trial Registration: TURING received ethical approval on 14 Jun 2019 - REC reference: 19/LO/0738. It is registered on EudraCT, with ID number: 2018-004611-50, with a start date of 2019-06-14. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.
- Author
-
Yoon, Soo-Young, Lee, Sooji, Lee, Kyeongmin, Kim, Jin Sug, Hwang, Hyeon Seok, Kronbichler, Andreas, Jacob, Louis, Shin, Ju-Young, Lee, Jin A., Park, Jaeyu, Lee, Hyeri, Lee, Hayeon, Jeong, Kyunghwan, and Yon, Dong Keon
- Subjects
ACUTE kidney failure ,DRUG side effects ,NEPHRITIS ,GROUP psychotherapy - Abstract
This study aims to figure out the worldwide prevalence of anticancer therapy-associated acute kidney injury (AKI) and tubulointerstitial nephritis (TIN) and the relative risk of each cancer drug. We conducted an analysis of VigiBase, the World Health Organization pharmacovigilance database, 1967–2023 via disproportionate Bayesian reporting method. We further categorized the anticancer drugs into four groups: cytotoxic therapy, hormone therapy, immunotherapy, and targeted therapy. Reporting odds ratio (ROR) and information component (IC) compares observed and expected values to investigate the associations of each category of anticancer drugs with AKI and TIN. We identified 32,722 and 2056 reports (male, n = 17,829 and 1,293) of anticancer therapy-associated AKI and TIN, respectively, among 4,592,036 reports of all-drug caused AKI and TIN. There has been a significant increase in reports since 2010, primarily due to increased reports of targeted therapy and immunotherapy. Immunotherapy exhibited a significant association with both AKI (ROR: 8.92; IC
0.25 : 3.06) and TIN (21.74; 4.24), followed by cytotoxic therapy (7.14; 2.68), targeted therapy (5.83; 2.40), and hormone therapy (2.59; 1.24) for AKI, and by cytotoxic therapy (2.60; 1.21) and targeted therapy (1.54; 0.61) for TIN. AKI and TIN were more prevalent among individuals under 45 years of age, with a female preponderance for AKI and males for TIN. These events were reported in close temporal relationship after initiation of the respective drug (16.53 days for AKI and 27.97 days for TIN), and exhibited a high fatality rate, with 23.6% for AKI and 16.3% for TIN. These findings underscore that kidney-related adverse drug reactions are of prognostic significance and strategies to mitigate such side effects are required to optimize anticancer therapy. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
9. Edema-like symptoms are common in ultra-distance cyclists and driven by overdrinking, use of analgesics and female sex – a study of 919 athletes
- Author
-
Gauckler, Philipp, Kesenheimer, Jana S., Kronbichler, Andreas, and Kolbinger, Fiona R.
- Published
- 2021
- Full Text
- View/download PDF
10. Replacing a kidney biopsy by exome sequencing in undetermined kidney diseases—not yet ready for prime time!
- Author
-
Torra, Roser, Kronbichler, Andreas, and Bajema, Ingeborg M
- Subjects
- *
RENAL biopsy , *KIDNEY diseases , *POLYCYSTIC kidney disease , *DIABETIC nephropathies - Abstract
The article discusses the use of exome sequencing (ES) as a potential alternative to kidney biopsies in diagnosing undetermined kidney diseases (UKD). While kidney biopsies are invasive and carry risks, recent studies have shown that genetic variants may explain a significant portion of UKD cases. ES involves sequencing the coding regions of all protein-coding genes in the human genome and has been successful in diagnosing certain genetic kidney disorders. However, the study emphasizes that ES does not provide a definitive diagnosis in all cases, and kidney biopsies should still be considered in certain situations. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
11. Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG).
- Author
-
Hilhorst, Marc, Bemelman, Frederike J, Bruchfeld, Annette, Fernandez-Juarez, Gema M, Floege, Jürgen, Frangou, Eleni, Goumenos, Dimitrios, Kooten, Cees van, Kronbichler, Andreas, Stevens, Kate I, Turkmen, Kultigin, Wiersinga, W Joost, and Anders, Hans-Joachim
- Subjects
SARS-CoV-2 ,COVID-19 ,COVID-19 treatment - Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic led to rapid vaccine development and large global vaccination schemes. However, patients with immune-mediated kidney disease, chronic kidney diseases and kidney transplant recipients show high non-response rates to vaccination despite more than three vaccinations and, consequently, reduced viral clearance capacity when infected while receiving certain immunosuppressants, carrying an elevated risk for coronavirus disease 2019 (COVID-19)-related morbidity and mortality. SARS-CoV-2 evolution has been characterized by the emergence of novel variants and spike mutations contributing to waning efficacy of neutralizing antibodies. To this end, the therapeutic field expands from vaccination towards a combined approach of immunization, pre-exposure prophylaxis and early post-exposure treatment using direct-acting antivirals and neutralizing monoclonal antibodies to treat early in the disease course and avoid hospitalization. This expert opinion paper from the Immunonephrology Working Group of the European Renal Association (ERA-IWG) summarizes available prophylactic and/or early treatment options (i.e. neutralizing monoclonal antibodies and direct-acting antivirals) of SARS-CoV-2-infected patients with immune-mediated kidney disease, chronic kidney disease and kidney transplant recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Challenges of defining renal response in ANCA-associated vasculitis: call to action?
- Author
-
Odler, Balazs, Bruchfeld, Annette, Scott, Jennifer, Geetha, Duvuru, Little, Mark A, Jayne, David R W, and Kronbichler, Andreas
- Subjects
CHRONIC kidney failure ,VASCULITIS ,KIDNEY physiology ,BIOMARKERS ,GLOMERULAR filtration rate ,KIDNEY glomerulus diseases - Abstract
Avoiding end-stage kidney disease in patients with anti-neutrophil cytoplasmic antibody–associated vasculitis (AAV) has a high therapeutic priority. Although renal response is a crucial measure to capture clinically relevant changes, clinal trials have used various definitions and no well-studied key surrogate markers to predict renal outcome in AAV exist. Differences in clinical features and histopathologic and therapeutic approaches will influence the course of kidney function. Its assessment through traditional surrogates (i.e. serum creatinine, glomerular filtration rate, proteinuria, hematuria and disease activity scores) has limitations. Refinement of these markers and the incorporation of novel approaches such as the assessment of histopathological changes using cutting-edge molecular and machine learning mechanisms or new biomarkers could significantly improve prognostication. The timing is favourable since large datasets of trials conducted in AAV are available and provide a valuable resource to establish renal surrogate markers and, likely, aim to investigate optimized and tailored treatment approaches according to a renal response score. In this review we discuss important points missed in the assessment of kidney function in patients with AAV and point towards the importance of defining renal response and clinically important short- and long-term predictors of renal outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Avacopan for ANCA-associated vasculitis – information for prescribers.
- Author
-
McGovern, Dominic, Jones, Rachel B, Willcocks, Lisa C, Smith, Rona M, Jayne, David R W, and Kronbichler, Andreas
- Subjects
VASCULITIS ,MICROSCOPIC polyangiitis - Abstract
The approval of avacopan as a treatment for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) by the US Food and Drug Administration (FDA) in 2021 and the European Medicines Agency (EMA) in 2022 represents an important therapeutic advance. Of the patients receiving avacopan, 13.3% suffered serious infections versus 15.2% in those in the prednisone group, and serious opportunistic infections were less common in patients receiving avacopan (3.6% in the avacopan group, 6.7% in the prednisone group) [[10]]. Insights from the ADVOCATE study: respiratory tract involvement in patients with ANCA-associated vasculitis in a randomized, double-blind, placebo-controlled, phase 3 trial of avacopan. Recovery of renal function among ANCA-associated vasculitis patients with baseline eGFR <=20 in the avacopan ADVOCATE trial. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
14. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021.
- Author
-
Anders, Hans-Joachim, Loutan, Jerome, Bruchfeld, Annette, Fernández-Juárez, Gema M, Floege, Jürgen, Goumenos, Dimitrios, Turkmen, Kultigin, Kooten, Cees van, Frangou, Eleni, Stevens, Kate I, Kronbichler, Andreas, Segelmark, Mårten, and Tesar, Vladimir
- Subjects
KIDNEY failure ,RENAL biopsy ,CHILD patients ,LUPUS nephritis ,CLINICAL indications ,KIDNEY diseases - Abstract
In 2019 and 2021, the European League for Rheumatism (EULAR) jointly with the European Renal Association (ERA) and the Kidney Disease: Improving Global Outcomes (KDIGO), respectively, released updated guidelines on the management of lupus nephritis (LN). The Immunology Working Group of the ERA reviewed and compared both updates. Recommendations were either consistent or differences were of negligible clinical relevance for: indication for kidney biopsy, kidney biopsy interpretation, treatment targets, hydroxychloroquine dosing, first-line initial immunosuppressive therapy for active class III, IV (±V) LN, pregnancy in LN, LN in paediatric patients and LN patients with kidney failure. Relevant differences in the recommended management relate to the recognition of lupus podocytopathies, uncertainties in steroid dosing, drug preferences in specific populations and maintenance therapy, treatment of pure class V LN, therapy of recurrent LN, evolving alternative drug options and diagnostic work-up of thrombotic microangiopathy. Altogether, both documents provide an excellent guidance to the growing complexity of LN management. This article endeavours to prevent confusion by identifying differences and clarifying discrepancies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Using a Network-Based Analysis Approach to Investigate the Involvement of S. aureus in the Pathogenesis of Granulomatosis with Polyangiitis.
- Author
-
Rowland, Gregory, Kronbichler, Andreas, Smith, Rona, Jayne, David, van der Graaf, Piet H., and Chelliah, Vijayalakshmi
- Subjects
- *
GRANULOMATOSIS with polyangiitis , *DISEASE relapse , *PATHOGENESIS , *SYMPTOMS , *STAPHYLOCOCCUS aureus , *MUPIROCIN - Abstract
Chronic nasal carriage of Staphylococcus aureus (SA) has been shown to be significantly higher in GPA patients when compared to healthy subjects, as well as being associated with increased endonasal activity and disease relapse. The aim of this study was to investigate SA involvement in GPA by applying a network-based analysis (NBA) approach to publicly available nasal transcriptomic data. Using these data, our NBA pipeline generated a proteinase 3 (PR3) positive ANCA associated vasculitis (AAV) disease network integrating differentially expressed genes, dysregulated transcription factors (TFs), disease-specific genes derived from GWAS studies, drug–target and protein–protein interactions. The PR3+ AAV disease network captured genes previously reported to be dysregulated in AAV associated. A subnetwork focussing on interactions between SA virulence factors and enriched biological processes revealed potential mechanisms for SA's involvement in PR3+ AAV. Immunosuppressant treatment reduced differential expression and absolute TF activities in this subnetwork for patients with inactive nasal disease but not active nasal disease symptoms at the time of sampling. The disease network generated identified the key molecular signatures and highlighted the associated biological processes in PR3+ AAV and revealed potential mechanisms for SA to affect these processes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Molecular Pathology, Diagnostics, and Therapeutics of Nephropathy.
- Author
-
Kronbichler, Andreas and Tesar, Vladimir
- Subjects
- *
MOLECULAR pathology , *KIDNEY diseases , *THERAPEUTICS , *POLYCYSTIC kidney disease - Abstract
Years of standing still have ended, and the field of nephrology has seen a plethora of clinical trials, changing the therapeutic landscape of chronic kidney disease (CKD) and immune-mediated kidney disease management. POP inhibition might be carried forward to develop therapies that aim to reduce the damage to kidneys caused by ischemia and reperfusion injury, such as after kidney transplantation. Overall, the provided results will further help to increase our understanding of kidney disease in more detail and will eventually lead to individualized treatment approaches for the plethora of kidney diseases. Kidney biopsies remain valuable to a final diagnosis and have achieved enormous value in predicting prognosis in several kidney diseases, such as anti-neutrophil cytoplasmic antibody (ANCA)-glomerulonephritis [[1]]. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
17. 2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.
- Author
-
Grayson, Peter C., Ponte, Cristina, Suppiah, Ravi, Robson, Joanna C., Gribbons, Katherine Bates, Judge, Andrew, Craven, Anthea, Khalid, Sara, Hutchings, Andrew, Danda, Debashish, Luqmani, Raashid A., Watts, Richard A., Merkel, Peter A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, and Carette, Simon
- Subjects
BLOOD pressure ,CONFIDENCE intervals ,RHEUMATOLOGY ,AGE distribution ,ANGINA pectoris ,TAKAYASU arteritis ,DIAGNOSTIC imaging ,SEX distribution ,DESCRIPTIVE statistics ,SENSITIVITY & specificity (Statistics) ,VASCULITIS ,INTERMITTENT claudication ,PULSE (Heart beat) - Abstract
Objective: To develop and validate new classification criteria for Takayasu arteritis (TAK). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 6 phases: 1) identification of candidate criteria items, 2) collection of candidate items present at diagnosis, 3) expert panel review of cases, 4) data‐driven reduction of candidate items, 5) derivation of a points‐based classification score in a development data set, and 6) validation in an independent data set. Results: The development data set consisted of 316 cases of TAK and 323 comparators. The validation data set consisted of an additional 146 cases of TAK and 127 comparators. Age ≤60 years at diagnosis and imaging evidence of large‐vessel vasculitis were absolute requirements to classify a patient as having TAK. The final criteria items and weights were as follows: female sex (+1), angina (+2), limb claudication (+2), arterial bruit (+2), reduced upper extremity pulse (+2), reduced pulse or tenderness of a carotid artery (+2), blood pressure difference between arms of ≥20 mm Hg (+1), number of affected arterial territories (+1 to +3), paired artery involvement (+1), and abdominal aorta plus renal or mesenteric involvement (+3). A patient could be classified as having TAK with a cumulative score of ≥5 points. When these criteria were tested in the validation data set, the model area under the curve was 0.97 (95% confidence interval [95% CI] 0.94–0.99) with a sensitivity of 93.8% (95% CI 88.6–97.1%) and specificity of 99.2% (95% CI 96.7–100.0%). Conclusion: The 2022 American College of Rheumatology/EULAR classification criteria for TAK are now validated for use in research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
18. 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.
- Author
-
Ponte, Cristina, Grayson, Peter C., Robson, Joanna C., Suppiah, Ravi, Gribbons, Katherine Bates, Judge, Andrew, Craven, Anthea, Khalid, Sara, Hutchings, Andrew, Watts, Richard A., Merkel, Peter A., Luqmani, Raashid A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, and Pagnoux, Christian
- Subjects
TEMPORAL arteries ,C-reactive protein ,RESEARCH evaluation ,BIOPSY ,CONFIDENCE intervals ,RESEARCH methodology ,GIANT cell arteritis ,SEVERITY of illness index ,BLOOD sedimentation - Abstract
Objective: To develop and validate updated classification criteria for giant cell arteritis (GCA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 6 phases: 1) identification of candidate items, 2) prospective collection of candidate items present at the time of diagnosis, 3) expert panel review of cases, 4) data‐driven reduction of candidate items, 5) derivation of a points‐based risk classification score in a development data set, and 6) validation in an independent data set. Results: The development data set consisted of 518 cases of GCA and 536 comparators. The validation data set consisted of 238 cases of GCA and 213 comparators. Age ≥50 years at diagnosis was an absolute requirement for classification. The final criteria items and weights were as follows: positive temporal artery biopsy or temporal artery halo sign on ultrasound (+5); erythrocyte sedimentation rate ≥50 mm/hour or C‐reactive protein ≥10 mg/liter (+3); sudden visual loss (+3); morning stiffness in shoulders or neck, jaw or tongue claudication, new temporal headache, scalp tenderness, temporal artery abnormality on vascular examination, bilateral axillary involvement on imaging, and fluorodeoxyglucose–positron emission tomography activity throughout the aorta (+2 each). A patient could be classified as having GCA with a cumulative score of ≥6 points. When these criteria were tested in the validation data set, the model area under the curve was 0.91 (95% confidence interval [95% CI] 0.88–0.94) with a sensitivity of 87.0% (95% CI 82.0–91.0%) and specificity of 94.8% (95% CI 91.0–97.4%). Conclusion: The 2022 American College of Rheumatology/EULAR GCA classification criteria are now validated for use in clinical research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis.
- Author
-
Berti, Alvise, Alsawas, Mouaz, Jawaid, Tabinda, Prokop, Larry J, Lee, Jiwon M, Jeong, Gwang Hun, Quintana, Luis F, Moiseev, Sergey, Vaglio, Augusto, Tesar, Vladimir, Geetha, Duvuru, Shin, Jae I l, and Kronbichler, Andreas
- Subjects
MYCOPHENOLIC acid ,REMISSION induction ,MICROSCOPIC polyangiitis ,CLINICAL trials ,VASCULITIS ,DISEASE remission - Abstract
Background Uncertainties exist about the use of mycophenolate mofetil (MMF) in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV), particularly for remission maintenance. Methods Systematic review and meta-analysis of phase II and III trials assessing the use of MMF in AAV, granulomatosis with polyangiitis and microscopic polyangiitis (MPA). A comprehensive search of several databases (Medline, EMBASE, Cochrane, Web of Science, Scopus) from inception to 5 May 2020 has been conducted. Trial data were extracted to estimate odds ratios (ORs) and estimates (ES) for MMF efficacy (remission-induction and maintenance). Severe adverse effects (SAEs) were collected. Results From 565 articles captured, 10 met the predefined criteria, 5 phase II and 5 III trials; 4 assessed remission-induction, 3 remission maintenance and 3 both. The pooled OR for remission-induction at 6 months was 1.06 (95% confidence interval 0.74, 1.52), with no significant difference by subgroup meta-analysis of trials stratified by different study-level features (i.e. kidney disease, MPA, myeloperoxidase-ANCA positivity, newly diagnosed disease) (P > 0.05). The overall ES for remission maintenance at the end of follow-up ranged between 51% and 91% (I
2 = 74.8%). Subgroup meta-analysis identified kidney involvement as a possible source of heterogeneity, yielding a significantly higher rate of sustained remission in trials enrolling only patients with kidney involvement (92%, 76–100%) versus those enrolling patients with and without kidney involvement (56%, 45–66%). Results were similar in multiple sensitivity analyses. During follow-up, the frequency of SAEs in MMF-based treatment arms was 31.8%. Conclusions In AAV, MMF use was significantly associated with higher sustained remission rates in trials enrolling only patients with kidney involvement. These findings might influence clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
20. Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Randomized Control Trials in the Pre-Delta Era: A Systematic Review and Network Meta-Analysis.
- Author
-
Oh, SuA, Purja, Sujata, Shin, Hocheol, Kim, Min Seo, Park, Seoyeon, Kronbichler, Andreas, Smith, Lee, Eisenhut, Michael, Shin, Jae Il, and Kim, Eunyoung
- Subjects
COVID-19 pandemic ,COVID-19 vaccines ,VACCINE safety ,IMMUNE response ,NEUTRALIZATION tests ,VACCINE effectiveness - Abstract
The most effective method of limiting the coronavirus disease pandemic of 2019 (COVID-19) is vaccination. For the determination of the comparative efficacy and safety of COVID-19 vaccines and their platforms during the pre-Delta era, a systematic review and network meta-analysis was conducted. The MEDLINE, Embase, and MedRxiv databases were searched, and the gray literature was manually searched up to 8 July 2021. The review includes the phase II and III randomized controlled trials (RCTs) that assessed the efficacy, immunogenicity, and safety of the COVID-19 vaccines. The network meta-analysis used a Bayesian model and used the surface under the cumulative ranking to rank the comparisons between the vaccines. All included studies were quality appraised according to their design, and the heterogeneity of the analyses was assessed using I2. In terms of vaccine efficacy, the mRNA-1273 vaccine ranked the highest, and the CoronaVac vaccine ranked the lowest. The mRNA-1273 ranked the highest for neutralizing antibody responses to live SARS-CoV-2. The WIV04 vaccine was associated with the lowest incidence of both local and systemic adverse reactions. All studies except one had a low to moderate risk of bias. The mRNA platform vaccines showed higher efficacy and more adverse reactions than the other vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS.
- Author
-
Stevens, Kate I, Frangou, Eleni, Shin, Jae I l, Anders, Hans-Joachim, Bruchfeld, Annette, Schönermarck, Ulf, Hauser, Thomas, Westman, Kerstin, Fernandez-Juarez, Gema M, Floege, Jürgen, Goumenos, Dimitrios, Turkmen, Kultigin, Kooten, Cees van, McAdoo, Stephen P, Tesar, Vladimir, Segelmark, Mårten, Geetha, Duvuru, Jayne, David R W, Kronbichler, Andreas, and (EUVAS), Immunonephrology Working Group (IWG) of the European Renal Association (ERA) and the European Vasculitis Society
- Subjects
COVID-19 ,COVID-19 vaccines ,VACCINE effectiveness ,BOOSTER vaccines ,HUMORAL immunity ,KIDNEY diseases - Abstract
Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or comorbidities and complications caused by the underlying disease. Humoral vaccine response, measured by the presence of antibodies, is impaired or absent in patients receiving rituximab, mycophenolate mofetil (MMF), higher doses of glucocorticoids and likely other immunosuppressants, such as cyclophosphamide. The timing between the use of these agents and administration of vaccines is associated with the level of immune response: with rituximab, vaccine response can only be expected once B cells start to recover and patients with transient discontinuation of MMF mount a humoral response more frequently. The emergence of new COVID-19 variants and waning of vaccine-induced immunity highlight the value of a booster dose and the need to develop mutant-proof vaccines. COVID-19 vaccines are safe, exhibiting a very low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. management of membranous nephropathy—an update.
- Author
-
Caravaca-Fontán, Fernando, Fernández-Juárez, Gema M, Floege, Jürgen, Goumenos, Dimitrios, Kronbichler, Andreas, Turkmen, Kultigin, Kooten, Cees van, Frangou, Eleni, Stevens, Kate I, Segelmark, Mårten, Tesar, Vladimir, Anders, Hans-Joachim, and Bruchfeld, Annette
- Subjects
KIDNEY diseases ,KIDNEY glomerulus diseases ,THERAPEUTICS ,DISEASE management ,CLINICAL trials - Abstract
In recent decades, several important advances have taken place in the understanding of the pathogenesis underlying membranous nephropathy (MN) that have sparked renewed interest in its management. Four landmark trials in MN and a fifth clinical trial—which was a pilot study—have been published in recent years. The results from some of these trials have had a significant impact on the recommendations included in the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases, representing a significant step forward compared with the previous guideline in several aspects, including diagnosis, disease monitoring and treatment strategies. However, considering the rapidly evolving advances in the knowledge of MN and the recent publication of the STARMEN and RI-CYCLO trials, several recommendations contained in the guideline warrant updates. This article provides a perspective of the Immunonephrology Working Group of the European Renal Association regarding the management of MN in native kidneys of adult patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis.
- Author
-
Robson, Joanna C., Grayson, Peter C., Ponte, Cristina, Suppiah, Ravi, Craven, Anthea, Judge, Andrew, Khalid, Sara, Hutchings, Andrew, Watts, Richard A., Merkel, Peter A., Luqmani, Raashid A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, Pagnoux, Christian, and Dhindsa, Navjot
- Subjects
CONSENSUS (Social sciences) ,EOSINOPHILS ,CONFIDENCE intervals ,RHEUMATOLOGY ,RESEARCH methodology ,PARANASAL sinus diseases ,ANTINEUTROPHIL cytoplasmic antibodies ,GRANULOMATOSIS with polyangiitis ,LOGISTIC regression analysis ,SENSITIVITY & specificity (Statistics) - Abstract
Objective: To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data‐driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points‐based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for GPA consisted of 578 cases of GPA and 652 comparators. The validation set consisted of an additional 146 cases of GPA and 161 comparators. From 91 candidate items, regression analysis identified 26 items for GPA, 10 of which were retained. The final criteria and their weights were as follows: bloody nasal discharge, nasal crusting, or sino‐nasal congestion (+3); cartilaginous involvement (+2); conductive or sensorineural hearing loss (+1); cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti–proteinase 3 ANCA positivity (+5); pulmonary nodules, mass, or cavitation on chest imaging (+2); granuloma or giant cells on biopsy (+2); inflammation or consolidation of the nasal/paranasal sinuses on imaging (+1); pauci‐immune glomerulonephritis (+1); perinuclear ANCA or antimyeloperoxidase ANCA positivity (−1); and eosinophil count ≥1 × 109/liter (−4). After excluding mimics of vasculitis, a patient with a diagnosis of small‐ or medium‐vessel vasculitis could be classified as having GPA if the cumulative score was ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 93% (95% confidence interval [95% CI] 87–96%) and the specificity was 94% (95% CI 89–97%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for GPA demonstrate strong performance characteristics and are validated for use in research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis.
- Author
-
Suppiah, Ravi, Robson, Joanna C., Grayson, Peter C., Ponte, Cristina, Craven, Anthea, Khalid, Sara, Judge, Andrew, Hutchings, Andrew, Merkel, Peter A., Luqmani, Raashid A., Watts, Richard A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, Pagnoux, Christian, and Dhindsa, Navjot
- Subjects
COMMITTEES ,CONFIDENCE intervals ,RHEUMATOLOGY ,ANTINEUTROPHIL cytoplasmic antibodies ,INTERSTITIAL lung diseases ,DESCRIPTIVE statistics ,LOGISTIC regression analysis ,GLOMERULONEPHRITIS ,ERYTHROCYTES ,MICROSCOPIC polyangiitis ,LONGITUDINAL method ,VASCULITIS - Abstract
Objective: To develop and validate classification criteria for microscopic polyangiitis (MPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data‐driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points‐based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for MPA consisted of 149 cases of MPA and 408 comparators. The validation set consisted of an additional 142 cases of MPA and 414 comparators. From 91 candidate items, regression analysis identified 10 items for MPA, 6 of which were retained. The final criteria and their weights were as follows: perinuclear antineutrophil cytoplasmic antibody (ANCA) or anti–myeloperoxidase‐ANCA positivity (+6), pauci‐immune glomerulonephritis (+3), lung fibrosis or interstitial lung disease (+3), sino‐nasal symptoms or signs (−3), cytoplasmic ANCA or anti–proteinase 3 ANCA positivity (−1), and eosinophil count ≥1 × 109/liter (−4). After excluding mimics of vasculitis, a patient with a diagnosis of small‐ or medium‐vessel vasculitis could be classified as having MPA with a cumulative score of ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 91% (95% confidence interval [95% CI] 85–95%) and the specificity was 94% (95% CI 92–96%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for MPA are now validated for use in clinical research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis.
- Author
-
Grayson, Peter C., Ponte, Cristina, Suppiah, Ravi, Robson, Joanna C., Craven, Anthea, Judge, Andrew, Khalid, Sara, Hutchings, Andrew, Luqmani, Raashid A., Watts, Richard A., Merkel, Peter A., Gatenby, Paul, Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, Pagnoux, Christian, and Dhindsa, Navjot
- Subjects
CONSENSUS (Social sciences) ,EOSINOPHILS ,CONFIDENCE intervals ,RHEUMATOLOGY ,RESEARCH methodology ,PARANASAL sinus diseases ,ANTINEUTROPHIL cytoplasmic antibodies ,CHURG-Strauss syndrome ,DESCRIPTIVE statistics ,LOGISTIC regression analysis ,SENSITIVITY & specificity (Statistics) - Abstract
Objective: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data‐driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points‐based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for EGPA consisted of 107 cases of EGPA and 450 comparators. The validation set consisted of an additional 119 cases of EGPA and 437 comparators. From 91 candidate items, regression analysis identified 11 items for EPGA, 7 of which were retained. The final criteria and their weights were as follows: maximum eosinophil count ≥1 × 109/liter (+5), obstructive airway disease (+3), nasal polyps (+3), cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti–proteinase 3 ANCA positivity (−3), extravascular eosinophilic predominant inflammation (+2), mononeuritis multiplex/motor neuropathy not due to radiculopathy (+1), and hematuria (−1). After excluding mimics of vasculitis, a patient with a diagnosis of small‐ or medium‐vessel vasculitis could be classified as having EGPA if the cumulative score was ≥6 points. When these criteria were tested in the validation data set, the sensitivity was 85% (95% confidence interval [95% CI] 77–91%) and the specificity was 99% (95% CI 98–100%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for EGPA demonstrate strong performance characteristics and are validated for use in research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.
- Author
-
Jung, Se Yong, Kim, Min Seo, Li, Han, Lee, Keum Hwa, Koyanagi, Ai, Solmi, Marco, Kronbichler, Andreas, Dragioti, Elena, Tizaoui, Kalthoum, Cargnin, Sarah, Terrazzino, Salvatore, Hong, Sung Hwi, Abou Ghayda, Ramy, Kim, Nam Kyun, Chung, Seo Kyoung, Jacob, Louis, Salem, Joe‐Elie, Yon, Dong Keon, Lee, Seung Won, and Kostev, Karel
- Subjects
COVID-19 ,CORONAVIRUS disease treatment ,DRUG side effects ,REMDESIVIR ,WORLD health ,PLURIPOTENT stem cells ,HUMAN stem cells - Abstract
On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing remdesivir prescriptions worldwide. However, potential cardiovascular (CV) toxicities associated with remdesivir remain unknown. We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO). Disproportionality analyses of CV‐ADRs associated with remdesivir were performed using reported odds ratios and information components. We conducted in vitro experiments using cardiomyocytes derived from human pluripotent stem cell cardiomyocytes (hPSC‐CMs) to confirm cardiotoxicity of remdesivir. To distinguish drug‐induced CV‐ADRs from COVID‐19 effects, we restricted analyses to patients with COVID‐19 and found that, after adjusting for multiple confounders, cardiac arrest (adjusted odds ratio [aOR]: 1.88, 95% confidence interval [CI]: 1.08–3.29), bradycardia (aOR: 2.09, 95% CI: 1.24–3.53), and hypotension (aOR: 1.67, 95% CI: 1.03–2.73) were associated with remdesivir. In vitro data demonstrated that remdesivir reduced the cell viability of hPSC‐CMs in time‐ and dose‐dependent manners. Physicians should be aware of potential CV consequences following remdesivir use and implement adequate CV monitoring to maintain a tolerable safety margin. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Development of crescentic membranoproliferative glomerulonephritis after COVID-19 vaccination.
- Author
-
Göndör, Gabor, Ksiazek, Sara H, Regele, Heinz, Kronbichler, Andreas, Knechtelsdorfer, Maarten, and Säemann, Marcus D
- Subjects
COVID-19 vaccines ,COVID-19 ,GLOMERULONEPHRITIS ,KIDNEY glomerulus diseases ,NEPHRITIS - Abstract
Membranoproliferative glomerulonephritis (MPGN) comprises a histologic pattern of glomerular injury with different underlying diseases. Here we report on a 47-year-old female with rapidly progressive glomerulonephritis (RPGN) on top of a previously diagnosed idiopathic MPGN after receiving the first dose of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) mRNA vaccine. After aggressive immunosuppression her serum creatinine returned to normal values, along with reduction of proteinuria. Recently, numerous publications have reported an association of glomerular diseases with COVID-19 vaccination. Our case presents to the best of our knowledge the first occurrence of possible association of COVID-19 mRNA vaccination with a crescentic form of MPGN. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Chest CT abnormalities in COVID-19: a systematic review.
- Author
-
Ghayda, Ramy Abou, Keum Hwa Lee, Jae Seok Kim, Seul Lee, Sung Hwi Hong, Kyeong Seok Kim, Kyeong Eon Kim, Jinhyn Seok, Hajeong Kim, Jangsuk Seo, Seungmin Lee, Ai Koyanagi, Jacob, Louis, Smith, Lee, Han Li, Kronbichler, Andreas, and Jae Il Shin
- Published
- 2021
- Full Text
- View/download PDF
29. The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis.
- Author
-
Odler, Balazs, Windpessl, Martin, Krall, Marcell, Steiner, Maria, Riedl, Regina, Hebesberger, Carina, Ursli, Martin, Zitt, Emanuel, Lhotta, Karl, Antlanger, Marlies, Cejka, Daniel, Gauckler, Philipp, Wiesholzer, Martin, Saemann, Marcus, Rosenkranz, Alexander R., Eller, Kathrin, and Kronbichler, Andreas
- Subjects
KIDNEY diseases ,AUTOIMMUNE diseases ,KIDNEY glomerulus diseases ,RITUXIMAB ,BODY mass index - Abstract
Objective: To characterize the incidence, type, and risk factors of severe infections (SI) in patients with autoimmune kidney diseases treated with rituximab (RTX). Methods: We conducted a multicenter retrospective cohort study of adult patients with immune-related kidney diseases treated with at least one course of RTX between 2015 and 2019. As a part of the ABCDE Registry, detailed data on RTX application and SI were collected. SI were defined by Common Terminology Criteria for Adverse Events v5.0 as infectious complications grade 3 and above. Patients were dichotomized between "nephrotic" and "nephritic" indications. The primary outcome was the incidence of SI within 12 months after the first RTX application. Results: A total of 144 patients were included. Twenty-five patients (17.4%) presented with SI, mostly within the first 3 months after RTX administration. Most patients in the nephritic group had ANCA-associated vasculitis, while membranous nephropathy was the leading entity in the nephrotic group. Respiratory infections were the leading SI (n= 10, 40%), followed by urinary tract (n=3, 12%) and gastrointestinal infections (n=2, 8%). On multivariable analysis, body mass index (BMI, 24.6 kg/m
2 versus 26.9 kg/m2 , HR: 0.88; 95%CI: 0.79-0.99; p=0.039) and baseline creatinine (HR: 1.25; 95%CI: 1.04-1.49; p=0.017) were significantly associated with SI. All patients in the nephritic group (n=19; 100%) who experienced a SI received oral glucocorticoid (GC) treatment at the time of infection. Hypogammaglobulinemia was frequent (58.5%) but not associated with SI. Conclusions: After RTX administration, impaired kidney function and lower BMI are independent risk factors for SI. Patients with nephritic glomerular diseases having concomitant GC treatment might be at higher risk of developing SI. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
30. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study.
- Author
-
Moiseev, Sergey, Kronbichler, Andreas, Makarov, Egor, Bulanov, Nikolay, Crnogorac, Matija, Direskeneli, Haner, Galesic, Kresimir, Gazel, Ummugulsum, Geetha, Duvuru, Guillevin, Loic, Hrušková, Zdenka, Little, Mark A, Ahmed, Adeel, McAdoo, Stephen P, Mohammad, Aladdin J, Moran, Sarah, Novikov, Pavel, Pusey, Charles D, Rahmattulla, Chinar, and Satrapová, Veronika
- Subjects
- *
THROMBOEMBOLISM risk factors , *SKIN diseases , *RESEARCH , *VEINS , *PULMONARY embolism , *CONFIDENCE intervals , *MULTIPLE regression analysis , *ANTINEUTROPHIL cytoplasmic antibodies , *MEDICAL cooperation , *TERTIARY care , *REGRESSION analysis , *RISK assessment , *KIDNEY diseases , *GRANULOMATOSIS with polyangiitis , *THROMBOEMBOLISM , *DESCRIPTIVE statistics , *STATISTICAL models , *ODDS ratio , *VASCULITIS , *MICROSCOPIC polyangiitis , *DISEASE complications - Abstract
Objective To investigate the occurrence of venous thromboembolic events (VTE) in a large cohort of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) across the European Union, Turkey, Russia, UK and North America. Methods Patients with a definite diagnosis of AAV who were followed for at least 3 months and had sufficient documentation were included. Data on VTE, including either deep vein thrombosis or pulmonary embolism, were collected retrospectively from tertiary vasculitis centres. Univariate and multivariate regression models were used to estimate odds ratios (ORs) and 95% CIs. Results Over a median follow-up of 63 (interquartile range: 29, 101) months, VTE occurred in 278 (9.7%) of 2869 AAV patients with a similar frequency across different countries (from 6.3% to 13.7%), and AAV subtype [granulomatosis with polyangiitis: 9.8% (95% CI: 8.3, 11.6%); microscopic polyangiitis: 9.6% (95% CI: 7.9, 11.4%); and eosinophilic granulomatosis with polyangiitis: 9.8% (95% CI: 7.0, 13.3%)]. Most VTE (65.6%) were reported in the first-year post-diagnosis. Multiple factor logistic regression analysis adjusted for sex and age showed that skin (OR 1.71, 95% CI: 1.01, 2.92), pulmonary (OR 1.78, 95% CI: 1.04, 3.14) and kidney [eGFR 15–60 ml/min/1.73 m2, OR 2.86 (95% CI: 1.27, 6.47); eGFR <15 ml/min/1.73 m2, OR 6.71 (95% CI: 2.94, 15.33)] involvement were independent variables associated with a higher occurrence of VTE. Conclusion Two-thirds of VTE occurred during the initial phase of active disease. We confirmed previous findings from smaller studies that a decrease in kidney function, skin involvement and pulmonary disease are independently associated with VTE. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Inhibition of clonal expansion of parietal epithelial cells and crescent–podocyte transition in severe glomerulonephritis: on the way to targeted therapy?
- Author
-
Mentese, Ilay Berke and Kronbichler, Andreas
- Subjects
- *
BORTEZOMIB , *PARIETAL cells , *EPITHELIAL cells , *LUPUS nephritis , *MYELOFIBROSIS , *GLOMERULONEPHRITIS , *STEM cell niches - Abstract
The human kidney possesses progenitor cells in the glomerular and tubular compartments of the nephron, capable of self-renewal, proliferation and differentiation. Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice. The crescent-forming PEC subset in humans was found to be characterized by expression of CD133, a marker of renal progenitor cells, and stratifin, a cell cycle checkpoint protein involved in stem cell proliferation/differentiation. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
32. Introduction to new CKJ section: In Context – in collaboration with YNP.
- Author
-
Craenenbroeck, Amaryllis van and Kronbichler, Andreas
- Subjects
- *
RESEARCH questions , *PODCASTING - Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.